(Q37826454)

23 August 2017

1 reference

title

Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review (English)

1 reference

23 August 2017

1 reference

Christopher R Chapple

4

0 references

author name string

S A Kaplan

1

1 reference

23 August 2017

C G Roehrborn

2

1 reference

23 August 2017

P Abrams

3

1 reference

23 August 2017

T Bavendam

5

1 reference

23 August 2017

Z Guan

6

1 reference

23 August 2017

7 January 2011

1 reference

International Journal of Clinical Practice

23 August 2017

1 reference

23 August 2017

65

1 reference

23 August 2017

4

1 reference

23 August 2017

487-507

1 reference

Prevalence and characteristics of lower urinary tract symptoms in men aged > or = 80 years

23 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Overactive bladder in the male patient: bladder, outlet, or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

The role of anticholinergic drugs in men with lower urinary tract symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Muscarinic receptor antagonists for overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Definition of at-risk patients: baseline variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Detrusor instability with equivocal obstruction: A predictor of unfavorable symptomatic outcomes after transurethral prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

The International Continence Society “Benign Prostatic Hyperplasia” Study: The Bothersomeness of Urinary Symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

Variability of Pressure-Flow Analysis Parameters in Repeated Cystometry in Patients with Benign Prostatic Hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02611.X

10.1111/J.1742-1241.2010.02611.X

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference